8-K
filed May 30, 2023, 7:59 PM ET
ticker BMRN
CIK 0001048477
other material
confidence high
sentiment neutral
materiality 0.40
BioMarin stockholders approve 14M share increase to equity plan at annual meeting
BIOMARIN PHARMACEUTICAL INC
- Stockholders elected all 11 director nominees; each received substantial majority support.
- Advisory vote on named executive officer compensation passed with 129.8M for, 24.5M against.
- Amendment to 2017 Equity Incentive Plan adding 14M shares approved by shareholders.
- KPMG LLP ratified as independent auditor for fiscal 2023; advisory vote on compensation frequency set to 1 year.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
BIOMARIN PHARMACEUTICAL INC shareholders approved Election of Directors.
- Proposal
- director election
- Outcome
- passed
Exact text from the filing
Proposal 1: Election of Directors Directors Elected Vote For Withheld Broker Non-Votes Mark J. Alles 132,590,721 23,270,276 10,893,446 Elizabeth McKee Anderson 143,554,881 12,306,116 10,893,446 Jean-Jacques Bienaimé 142,990,946 12,870,051 10,893,446 Willard Dere, M.D. 148,341,372 7,519,625 10,893,446 Elaine J. Heron, Ph.D. 145,753,472 10,107,525 10,893,446 Maykin Ho, Ph.D. 154,901,420 959,577 10,893,446 Robert J. Hombach 149,263,399 6,597,598 10,893,446 V. Bryan Lawlis, Ph.D. 150,808,310 5,052,687 10,893,446 Richard A. Meier 151,345,310 4,515,687 10,893,446 David E.I. Pyott, M.D. (Hon.) 147,242,636 8,618,361 10,893,446 Dennis J. Slamon, M.D., Ph.D. 154,624,428 1,236,569 10,893,446
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
BIOMARIN PHARMACEUTICAL INC shareholders approved Advisory Vote on Frequency of Advisory Vote on the Compensation of Named Executive Officers.
- Proposal
- say on pay frequency
- Outcome
- passed
Exact text from the filing
Proposal 3: Advisory Vote on Frequency of Advisory Vote on the Compensation of Named Executive Officers The advisory (non-binding) vote on the frequency of the advisory vote to approve the compensation of BioMarin’s named executive officers, as set forth in the Proxy Statement, received the following votes: 1 Year 2 Years 3 Years Abstain Broker Non-Votes 154,888,549 50,595 876,495 45,358 10,893,446
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
BIOMARIN PHARMACEUTICAL INC shareholders approved Advisory Vote on the Compensation of Named Executive Officers.
- Proposal
- say on pay
- Outcome
- passed
Exact text from the filing
Proposal 4: Advisory Vote on the Compensation of Named Executive Officers The advisory (non-binding) vote to approve the compensation of BioMarin’s named executive officers, as set forth in the Proxy Statement, received the following votes: For Against Abstain Broker Non-Votes 129,779,900 24,543,430 1,537,667 10,893,446
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
BIOMARIN PHARMACEUTICAL INC shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2023-12-31 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-12-31
Exact text from the filing
Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The ratification of the selection of KPMG LLP as BioMarin’s independent registered public accounting firm for the fiscal year ending December 31, 2023, as set forth in the Proxy Statement, received the following votes: For Against Abstain 159,510,686 7,133,289 110,468
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
BIOMARIN PHARMACEUTICAL INC shareholders approved Approval of an Amendment to the 2017 Equity Incentive Plan.
- Proposal
- equity plan
- Outcome
- passed
Exact text from the filing
Proposal 5: Approval of an Amendment to the 2017 Equity Incentive Plan The approval of the Plan Amendment received the following votes: For Against Abstain Broker Non-Votes 138,471,429 17,279,619 109,949 10,893,446
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.